Under construction – not a live service
Sign in
Enrolling by invitationNo phase

Standard versus tailored FVIII dosing and joint health in severe hemophilia A

Compares standard and tailored FVIII dosing in severe hemophilia A.

Key facts

Who runs it
Chulalongkorn University
Where
Bangkok, ThailandSee the site
Trial code
Registry title
Cartilage Biomarkers and HEAD-US Score in Severe Hemophilia A Patients Receiving FVIII Prophylaxis
Status
Enrolling by invitation
People taking part
19 people, planned
Started
1 Apr 2024
Planned end
28 Feb 2025
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • HEAD-US
  • Urinary carboxy-terminal cross linked telopeptide of type II collagen
  • Inflammatory markers
Record updated
10 February 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for people with severe hemophilia A who have had regular low dose FVIII prophylaxis and have no FVIII inhibitor.

Sex
All sexes can join.
Disease stage
Severe hemophilia A.
Earlier treatment
Standard low dose FVIII prophylaxis 1-3 times per week for at least 6 months before joining.
Biomarker or test result
No history of FVIII inhibitor (<0.6 Bethesda unit/ml).

Main reasons for not taking part

  • Another condition affecting the joints, such as osteoarthritis or metabolic bone disease

The registry criteria, word for word

Show all 5 criteriaShow less

Who can take part

  • patients with severe hemophilia A
  • previously receiving standard low dose FVIII prophylaxis 1-3 times per week for at least 6 months prior to enrollment in the project
  • no history of FVIII inhibitor (<0.6 Bethesda unit/ml)
  • obtained consent from both patients and their parents

Who cannot take part

  • patients with underlying condition affecting the joints such as osteoarthritis, metabolic bone disease, etc

Where in Thailand

  • Pediatric Department, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial HospitalBangkok, ThailandNo longer taking part

About the trial

What the trial wants to find out

Patients with severe hemophilia A often develop joint complication requiring careful monitoring. This study aimed to compare the effectiveness of standard low dose weight-based FVIII concentrates (CFCs) prophylaxis with pharmacokinetic-guided extended half-life FVIII concentrates (eHLFVIII) using cartilage biomarkers and HEAD-US score.

The 2 groups in the trial

  • Standard low dose FVIII prophylaxisTreatment being tested

    Standard weight based low dose FVIII concentrates prophylaxis

    Treatment: HEAD-US, Urinary carboxy-terminal cross linked telopeptide of type II collagen, and Inflammatory markers

  • PK guided Extended half life FVIII prophylaxisExisting treatment, for comparison

    Pharmacokinetic guided extended half life FVIII prophylaxis

    Treatment: HEAD-US, Urinary carboxy-terminal cross linked telopeptide of type II collagen, and Inflammatory markers

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Cartilage Biomarkers and HEAD-US Score in Severe Hemophilia A Patients Receiving Low Dose FVIII Prophylaxis
Plain-language title
Standard versus tailored FVIII dosing and joint health in severe hemophilia AGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
10 February 2025